Corporate Sponsors

The Association for Pathology Informatics gratefully acknowledges the financial support given by Corporate Sponsors.


 

Clinisys is a global provider of intelligent diagnostic informatics solutions and expertise designed to redefine the modern laboratory, across healthcare, life sciences and public health. Millions of diagnostic results and data insights are generated every day using Clinisys’ platform and cloud-based solutions in over 3,000 laboratories across 34 countries. Headquartered in Tucson, Arizona and Chertsey, England, Clinisys’ mission is to enhance the effectiveness of diagnostic workflows in any laboratory or testing environment and keep citizens and communities healthier and safer. To learn more visit www.clinisys.com.


 

Gestalt Diagnostics is a private, profit-driven software company who has developed PathFlow, an enterprise software platform specifically designed to bring the benefits of digital workflow to pathologists and pathology laboratories. This product was originally developed, by what is now Gestalt’s team, to support a fully digital reading platform for radiology. The radiology platform is used in leading hospitals across the United States and supports more than 15 million studies annually. Gestalt has expanded and redesigned this proven, robust solution to work in the laboratory space – engineered for the unique needs and workflow of pathologists.


 

Hamamatsu Photonics products and technology include optical sensors, light sources, and systems that use these components. They are applied to various new technologies and devices to support people’s lives and to help achieve a more comfortable and prosperous society. For example, our products are widely used for state-of-the-art medical equipment, test and inspection systems, microscopes that reveal the functions of cells, and giant telescopes that explore the mysteries of the universe.


Ibex is the pioneer in applying computational pathology to cancer diagnostics. Based out of Tel Aviv, Israel, the company's machine learning experts, data scientists and pathologists use artificial intelligence (AI) to develop clinical grade algorithms that can detect prostate cancer as accurately as a human pathologist.

Pathologists are challenged to provide accurate and timely analysis as the number of tests increases year-over-year.  In an effort to improve their workflow, pathology labs are starting to adopt digital technologies, including AI-based analysis of biopsies.  Ibex's algorithms analyzes biopsy images, detects cancerous cells, grades them and can also detect other clinically significant features.  The analysis is presented to pathologists either before or after reviewing the case, helping them in reducing error rates and improving operational efficiency by reducing the average time spent on a case.

Deployed in Israel, Europe and the United States, Ibex's solution is the first-ever AI-based cancer diagnosis solution in routine clinical use in a pathology lab and has already demonstrated success in detecting missed cancer cases.  The first application Ibex released is for prostate and breast and it works on expanding to additional tissues.  Ibex recently raised $15 million from prominent VC funds and corporate investors.


 

LigoLab is an award-winning provider of innovative end-to-end healthcare software for pathology laboratories, servicing 150+ facilities nationwide. As a comprehensive enterprise-grade solution, the LigoLab LIS & RCM Laboratory Operating Platform™ includes modules for anatomic pathology, clinical pathology, molecular diagnostics, revenue cycle management, and direct-to-consumer, all on one powerful and integrated platform that supports every role, every department, and every case. LigoLab empowers laboratories to serve patients better, differentiate themselves in the marketplace, scale their operations and become more compliant, and more profitable.


NovoPath 360 laboratory information system (LIS system) is raising the bar for how diagnostic labs operate. Helping relieve the unnecessary stressors experienced in day-to-day operations with streamlined workflows and advanced capabilities.

Designed as a single web-based platform packed with specialized workflows, tools, and seamless interoperability – you’ll find your lab accessioning, diagnosing, and releasing reports faster than ever.

Visiopharm® is a world leader in AI-driven precision pathology software.

Visiopharm’s pioneering image analysis tools support thousands of scientists, pathologists, and image analysis experts in academic institutions, biopharmaceutical industry, and diagnostic centers. AI-based image analysis and tissue mining tools support research and drug development research worldwide, while CE-IVD APPs support primary diagnostics. With the most advanced and sophisticated artificial intelligence and deep learning, Visiopharm delivers tissue data mining tools, precision results, and workflows.

 
Visiopharm was founded in 2001 and is privately owned. The company operates internationally with over 900 licenses and countless users. The company headquarters are in Denmark’s Medicon Valley, with offices in Sweden, England, Germany, and the United States.